|
Infliximab in Treating Patients With Myelodysplastic Syndrome Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Infliximab in Treating Patients With Myelodysplastic Syndrome conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Infliximab in Treating Patients With Myelodysplastic Syndrome Clinical research trials and Infliximab in Treating Patients With Myelodysplastic Syndrome health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Infliximab in Treating Patients With Myelodysplastic Syndrome. Infliximab in Treating Patients With Myelodysplastic Syndrome Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Infliximab in Treating Patients With Myelodysplastic Syndrome clinical trial. Subjects frequently get the best healthcare possible for their Infliximab in Treating Patients With Myelodysplastic Syndrome condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Infliximab in Treating Patients With Myelodysplastic Syndrome  Infliximab in Treating Patients With Myelodysplastic Syndrome
Infliximab in Treating Patients With Myelodysplastic Syndrome
For Condition: secondary myelodysplastic syndromes,previously treated myelodysplastic syndromes,refractory anemia with ringed sideroblasts,refractory anemia with excess blasts,de novo myelodysplastic syndromes,Refractory Anemia
Status: Recruiting
Sponsor(s): EORTC Leukemia Cooperative Group ,
Synopsis: RATIONALE: Monoclonal antibodies, such as infliximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomizedphase II trial to study the effectiveness of infliximab in treating patients who have myelodysplastic syndrome.
Details: OBJECTIVES: - Determine the therapeutic activity of 2 different doses of infliximab on peripheral blood cell count and peripheral and bone marrow blast cell count in patients with low- or intermediate-risk myelodysplastic syndromes. - Determine the subjective and objective toxicity of these regimens in these patients. - Determine the response rates (complete and partial response and hematological improvement) in patients treated with these regimens. - Determine the duration of response in patients treated with these regimens. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to cytogenetics (good vs intermediate vs unknown due to failure), overall International Prognostic Scoring System score (low [0] vs intermediate 1 [0.5-1.0] vs intermediate 2 [1.5-2.0]), and participating center. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive infliximab IV on days 1, 15, 43, 71, 99, 127, 155, and 183 in the absence of disease progression or unacceptable toxicity. - Arm II: Patients receive a higher dose of infliximab as in arm I. Patients achieving response (complete or partial response or hematological improvement) continue therapy beyond day 183 in the absence of disease progression. Patients are followed at 2 weeks and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 80 patients (40 per treatment arm) will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Confirmed diagnosis (within the past month) of low- or intermediate-risk myelodysplastic syndromes (MDS) meeting all of the following criteria: - No more than 10% bone marrow blasts (corresponding to refractory anemia [RA], RA with ringed sideroblasts, or RA with excess blasts) - Meets at least 1 of the following hematopoietic criteria: - Hemoglobin no greater than 10 g/dL OR red blood cell transfusion dependent - Neutrophil count no greater than 1,500/mm^3 - Platelet count no greater than 100,000/mm^3 OR platelet transfusion dependent - No poor cytogenetics (complex abnormalities or involvement of chromosome 7) - Patients with unknown cytogenetics may be eligible provided reasonable efforts have been made for determining the cytogenetic profile and the results are considered a failure (e.g., normal karyotype [NN] with no more than 10 metaphases) PATIENT CHARACTERISTICS: Age - 18 and over Performance status - WHO 0-2 Life expectancy - Not specified Hematopoietic - See Disease Characteristics Hepatic - No history of documented hepatitis C - No documented active hepatitis B - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - ALT less than 2.5 times ULN Renal - Creatinine less than 1.5 times ULN Cardiovascular - No New York Heart Association class III or IV heart disease - No clinical history or evidence of congestive heart failure - No severe cardiac dysfunction - LVEF greater than 35% Pulmonary - No prior or concurrent active or latent tuberculosis (TB) - No evidence of prior or concurrent active TB (i.e., fibrotic or pleural scarring, pulmonary nodules, mediastinal and/or hilar lymphadenopathy, upper lobe volume loss, or cavitation) by chest x-ray - Negative intradermal tuberculin skin test (i.e., induration less than 5 mm) - No severe pulmonary dysfunction Immunologic - No prior or concurrent opportunistic infection (e.g., herpes zoster, cytomegalovirus, Pneumocystic carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within the past 6 months - No concurrent severe (CTC grade III or IV) active, chronic, or recurrent infections - No recent history of allergies - HIV negative Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study participation - No prior clinically significant adverse event to murine or chimeric proteins or human/murine recombinant products - No recent contact with an individual with active TB - No poor medical risk due to other systemic disease - No multiple sclerosis or other demyelinating disorder - No peripheral neuropathy greater than CTC grade 1 - No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer - No psychological, familial, sociological, or geographical condition that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy - No prior infliximab or other monoclonal antibodies - At least 6 weeks since prior hematopoietic growth factors for MDS - At least 3 months since prior therapy targeted at reducing tumor necrosis factor (TNF) alpha (e.g., pentoxifylline, thalidomide, or etanercept) - No other concurrent drugs targeted at reducing TNF alpha (e.g., pentoxifylline, thalidomide, or etanercept) Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - No prior solid organ transplantation - Corneal transplantation more than 3 months ago allowed Other - No prior randomization to this clinical trial - At least 6 weeks since prior treatment for MDS (except supportive care) - No other concurrent investigational agents - No other concurrent anticancer therapy - No concurrent therapeutic-dose nonsteroidal anti-inflammatory drugs (NSAIDs) - Concurrent sporadic (no more than 3 tablets/week) over-the-counter NSAIDs allowed - Concurrent cardioprotective doses (80 mg/day or equivalent) of aspirin allowed
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ClaudioDenzlinger, , Vinzenz Von Paul Kliniken GMBH
Innsbruck Universitaetsklinik *Recruiting*
Innsbruck, , A-6020
Austria
Recruiting Contact Person 43-512-504-2971
Additional Information:
Study ID Numbers: CDR0000341685; EORTC-06023
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00074074
Other De Novo Myelodysplastic Syndromes Studies:
1. Infliximab in Treating Patients With Myelodysplastic Syndrome
2. Decitabine in Treating Patients With Myelodysplastic Syndrome
3. Thalidomide in Treating Patients With Myelodysplastic Syndrome
4. Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
5. Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
Related Studies:
Other de novo myelodysplastic syndromes Clinical Trials
Other Clinical Trials
Other Innsbruck Clinical Trials
Infliximab in Treating Patients With Myelodysplastic Syndrome
|
|
|
|
|
|
|
|
